LONDON, Nov. 29, 2018 /PRNewswire/ -- Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025Download the full report: https://www.reportbuyer.com/product/5591577
The global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is projected to reach $65,427 million by 2025, registering a CAGR of 25.6% from 2018 to 2025.Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1). Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in incidence of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.The global immune checkpoint inhibitor market is segmented based on type, application, and region. On the basis of type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The applications covered in the study include lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.KEY MARKET SEGMENTSBy TypeCTLA-4 InhibitorPD-1 InhibitorPD-L1 InhibitorBy ApplicationLung CancerBladder CancerMelanomaHodgkin LymphomaOthersBy RegionNorth AmericaU.S.CanadaMexicoEuropeGermanyFranceUKRest of EuropeAsia-PacificJapanChinaAustraliaIndiaRest of Asia-PacificLAMEABrazilRest of LAMEALIST OF KEY PLAYERS PROFILED IN THE REPORTAstraZeneca PLCBristol-Myers Squibb CompanyEli Lilly and Company (ARMO Biosciences)Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)F. Hoffmann-La Roche Ltd. (Genentech, Inc.)Immutep LimitedMerck & Co., Inc.Merck KGaA (EMD Serono, Inc.)Novartis AGPfizer Inc.LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)Incyte CorporationNewLink GeneticsDownload the full report: https://www.reportbuyer.com/product/5591577
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +1 (718) 213 4904 Website: www.reportbuyer.com
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-global-immune-checkpoint-inhibitors-market-was-valued-at-10-540-million-in-2017--and-is-projected-to-reach-65-427-million-by-2025--registering-a-cagr-of-25-6-from-2018-to-2025--300757792.html
SOURCE ReportBuyer
